For this reason, several existing medications to treat type 2 diabetes, such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors, are being tested in subjects with T1D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.